Recently, news has been trickling out that Rabbi Norman Lamm, the powerful former president of Yeshiva University, has resigned from the post he held as chancellor of that institution over the past decade. According to some reports, Lamm has been suffering from health problems for several years. In his resignation letter, written with help from his family, Lamm expresses regret for concealing certain allegations of sex abuse at Yeshiva—allegations […]
MolMed ASCO Prolonged Survival Times Patients With Acute Leukaemia Treated With TK
Long-term data presented at ASCO confirm prolonged survival times of patients with acute leukaemia treated with TK cell therapy The use of TK has enabled the execution of haploidentical donor transplants, with an overall survival similar to transplants from fully compatible donors MolMed expects to file a request for Conditional Marketing Authorisation of TK to […]
MolMed ASCO 2013: New data presented on NGR-hTNF
New data presented at ASCO on NGR-hTNF: significantly increase in survival in squamous NSCLC and clinical benefit in sarcomas – Final results from a randomised Phase II study indicate a 50% relative reduction in the risk of death in first-line squamous lung cancer – Optimal treatment regimen with statistically significant improvement in progression […]
MolMed TK Shareholders’ Meeting approves the Financial Statements 2012
MolMed Shareholders’ Meeting approves the Financial Statements 2012 and appoints members of Board of Directors and Board of Statutory AuditorsMeeting of the new Board of Directors: appointment of the Chief Executive Officer and of the members of the Board Committees The Shareholders’ Meeting of MolMed S.p.A. (MLM.MI), chaired by Professor Claudio Bordignon, met today […]
MolMed TK: Expiry deadline for submitting lists Board of Statutory Auditors
Expiry of extended deadline for submitting lists for the appointment of the Board of Statutory Auditors: no lists were presented by minority Shareholders With reference to the Shareholders’ Meeting of MolMed S.p.A. (MLM.MI), convened for 22 April 2013 on single call to decide, among other items, on the appointment of members of the Board of […]
MolMed TK: Bod approves draft financial statements for fiscal year 2012
The Board of Directors of MolMed S.p.A. (MLM.MI), chaired by Professor Claudio Bordignon, today reviewed and approved the draft financial statements at 31 December 2012. The most relevant elements concerning product development and activity progress were. TK: started registrative procedures and dossier preparation to file a market authorization application through an accelerated procedure (Conditional Marketing Authorisation) with […]